<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="206">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333420</url>
  </required_header>
  <id_info>
    <org_study_id>IFX-1-P2.9</org_study_id>
    <nct_id>NCT04333420</nct_id>
  </id_info>
  <brief_title>Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia</brief_title>
  <acronym>PANAMO</acronym>
  <official_title>A Pragmatic Adaptive Randomized, Controlled Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InflaRx GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InflaRx GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II &amp; Phase III:

      This is a pragmatic, adaptive, randomized, multicenter phase II/III study evaluating IFX-1
      for the treatment of COVID-19 related severe pneumonia. The study consists of two parts:
      Phase II, an open-label, randomized, 2-arm phase evaluating best supportive care (BSC) +
      IFX-1 (Arm A) and BSC alone (Arm B); and Phase III, a double-blind, placebo-controlled,
      randomized phase comparing standard of care (SOC) + IFX-1 (Arm A) versus SOC +
      placebo-to-match (Arm B)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Phase II: Open label study (30 patients) Phase III: Double- blind; (360 patients)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>28-day all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Emergent Adverse Events</measure>
    <time_frame>Day1 to Day 60</time_frame>
    <description>Frequency, severity, and relatedness to study drug of serious and non-serious TEAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Parameters</measure>
    <time_frame>Day 15, Day 28</time_frame>
    <description>Proportion of patients with an improvement in the 8-point ordinal scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Severe COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Arm A: SOC + IFX-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : SOC + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC + IFX-1</intervention_name>
    <description>SOC + IFX-1</description>
    <arm_group_label>Arm A: SOC + IFX-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC + Placebo</intervention_name>
    <description>SOC + Placebo</description>
    <arm_group_label>Arm B : SOC + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age or older

          -  Clinically evident or otherwise confirmed severe pneumonia

          -  SARS-CoV-2 infection confirmation (tested positive in last 14 days before
             randomization with locally available test system)

        Exclusion Criteria:

          -  Known history of progressed COPD as evidenced by use of daily maintenance treatment
             with long-acting bronchodilators or inhaled/oral corticosteroids for &gt; 2 months

          -  Patient moribund or expected to die in next 24h according to the judgment of the
             investigator

          -  Known severe congestive heart failure (New York Heart Association [NYHA] Class III- IV

          -  Received organ or bone marrow transplantation in past 3 months

          -  Known cardio-pulmonary mechanical resuscitation in past 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A Vlaar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Korinna Pilz, MD</last_name>
    <phone>+49 89 4141 89 78</phone>
    <phone_ext>0</phone_ext>
    <email>korinna.pilz@inflarx.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Vlaar, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L.M.A Heunks, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter van Paassen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 related severe pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

